blinatumomab + pembrolizumab
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-Cell Acute Lymphoblastic Leukemia, Adult
Conditions
B-Cell Acute Lymphoblastic Leukemia, Adult
Trial Timeline
Aug 4, 2017 → Jun 23, 2023
NCT ID
NCT03160079About blinatumomab + pembrolizumab
blinatumomab + pembrolizumab is a phase 1/2 stage product being developed by Merck for B-Cell Acute Lymphoblastic Leukemia, Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT03160079. Target conditions include B-Cell Acute Lymphoblastic Leukemia, Adult.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03340766 | Phase 1 | Completed |
| NCT03160079 | Phase 1/2 | Completed |
Competing Products
20 competing products in B-Cell Acute Lymphoblastic Leukemia, Adult